Mastitis is an acute inflammation of an interlobular connective tissue within the mammary gland. The inflammation results in swelling, warmth, breast pain, and redness. It most commonly affects women who are breast-feeding (lactation mastitis). Milk trapped in the breast is a main cause of mastitis. Some other causes are bacteria enter in breast and blocked milk duct.
Some of the signs and symptoms are breast tenderness or warmth to the touch, thickening of breast tissue or a breast lump, breast swelling, skin redness often in a wedge-shaped pattern, generally feeling ill, pain or a burning sensation continuously or while breast-feeding and fever of 101 F (38.3 C) or greater. Besides this, few of the risk factors include previous bout of mastitis while breast-feeding, improper nursing technique, sore or cracked nipples, poor nutrition, and becoming overly tired or stressed.
According to study, “Mastitis Market Research Report Information by Type (Human, Bovine), by Treatment (Antibiotics, Pain Relievers, Surgery, Vaccines, Others), by End-user (Hospitals and Clinics, Veterinary Centers, Others) and Region – Global Forecast till 2023” the key companies operating in the mastitis market are Merck Co & Inc., Pfizer Inc., Astellas Pharma Inc., Novartis AG, Bayer AG, Oncothyreon Inc., BioNumerik Pharmaceuticals Inc., Oncogenex, Apthera Inc., Boehringer Ingelheim GmbH, Zoetis Inc.
Based on type, mastitis market is segmented into bovine and human. Bovine type includes environmental mastitis, contagious mastitis and opportunist mastitis. Human type includes infectious mastitis and non-infectious mastitis. Based on treatment, market is segmented into surgery & radiation therapy, chemotherapy, biologic therapy, targeted therapy and hormone therapy. Chemotherapy treatment includes anthracyclines, antimetabolites and taxanes & alkylating agents. Targeted therapy includes tyrosine kinase inhibitors &monoclonal antibodies. Additionally, Hormone therapy includes aromatase inhibitors and selective estrogen-receptor modulators (SERMs). In addition, based on end-user, market is segmented into hospital & clinics and veterinary centers.
The mastitis market is driven by growth in rate of pregnancy, followed by rise in cases of breast cancer increase in prevalence of mastitis among the bovine population, rise in government initiatives to promote healthy breastfeeding, and unhygienic barn conditions causing contagious mastitis in bovines. However, rise in complications in diagnosis owing to similar symptoms of breast cancer & mastitis and lack of awareness among people may impact the market. Moreover, growth in developing economies is a key opportunity for market.
Based on geography, the Asian-Pacific region holds major share in mastitis market owing to rapidly developing the economy, huge healthcare spending, rise in availability of technology, growth in government initiatives for research & development (R&D) and increase in healthcare expenditure in the region. The North-American and European regions are estimated to witness considerable growth rate due to growth in technological advancement in the healthcare and increase in number of patient population for mastitis over the forecast period. In upcoming years, it is projected that the market will be reached at quick speed on account of increase in focus of various government agencies on treating mastitis during the forecast period. The global market is growing at a CAGR of 15.07% by directing the value of US $7,898.05 million during the forecast period (2017-2023).
For more information, refer to below link:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
